Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07307768 · ClinicalTrials.gov registry record · Phase 1

Ketamine Biomarker Validation

A Phase 1 study, sponsored by Soterix Medical.

Not yet
Registry status
Phase 1
Development phase
20
Enrollment target

NCT07307768: Clinical Trial Phase 1 study, sponsored by Soterix Medical.

NCT07307768 is a Phase 1 study that has not yet begun recruiting, run by Soterix Medical. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07307768, a Phase 1 study, has not yet begun recruiting, sponsored by Soterix Medical.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.

Primary Outcome

Twenty-two question Depression rating scale (excluding the two questions on weight loss and diurnal variation)

Interventions

  • DRUG Ketamine (0.5 mg/kg)
  • DRUG Ketamine (0.25 mg/kg)
  • DRUG Ketamine (0.75 mg/kg)

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-12-20
Est. Completion 2028-03-01
Phase Phase 1
Soterix Medical

8 total trials

What is known before NCT07307768 opens enrollment

NCT07307768 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 3 interventions - of which Ketamine (0.5 mg/kg) is the first listed.

NCT07307768 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07307768 about?

NCT07307768 is a clinical study titled "Ketamine Biomarker Validation". We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.

What is the current status of trial NCT07307768?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-20. Estimated completion is 2028-03-01.

What interventions are being tested in trial NCT07307768?

The interventions under investigation include: Ketamine (0.5 mg/kg) (DRUG), Ketamine (0.25 mg/kg) (DRUG), Ketamine (0.75 mg/kg) (DRUG).

Who is sponsoring clinical trial NCT07307768?

This trial is sponsored by Soterix Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07307768's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07307768, the US trial registry maintained by the National Library of Medicine. NCT07307768 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.